Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 13/20 | 0.72 |
| ▸ | KIT | P10721 | 9/20 | 0.72 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | SRC | P12931 | 9/20 | 0.53 |
| ▸ | LCK | P06239 | 5/20 | 0.53 |
| ▸ | FYN | P06241 | 5/20 | 0.53 |
| ▸ | YES1 | P07947 | 5/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144862 | 1.00 | KDR (0.72) | KDRPDGFRBKITAURKASRC | |
| SCHEMBL3144446 | 0.99 | KDR (0.71) | KDRPDGFRBKITAURKASRC | |
| SCHEMBL3144459 | 0.99 | KDR (0.71) | KDRPDGFRBKITAURKASRC | |
| SCHEMBL3143916 | 0.95 | KDR (0.79) | KDRPDGFRBKITAURKASRC | |
| SCHEMBL3143907 | 0.95 | KDR (0.79) | KDRPDGFRBKITAURKASRC | |
| SCHEMBL3140243 | 0.90 | PDGFRB (0.79) | KDRPDGFRBKITAURKASRC | |
| SCHEMBL3140264 | 0.90 | PDGFRB (0.79) | KDRPDGFRBKITAURKASRC | |
| SCHEMBL14212196 | 0.89 | KDR (0.71) | KDRPDGFRBKITAURKASRC | |
| SCHEMBL3133205 | 0.88 | PDGFRB (0.92) | KDRPDGFRBKITAURKALCK | |
| SCHEMBL3133199 | 0.88 | PDGFRB (0.92) | KDRPDGFRBKITAURKALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| EP-2157093-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | MTOR, PKN2, MAP3K15 | KDR 1780/4885PDGFRB 651/4885KIT 907/4885 |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | PRKACA, PACSIN2, PRKACB | KDR 2952/4885PDGFRB 2129/4885KIT 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.